SPECT imaging with 111In-octreotide for the localization of pancreatic insulinoma

Q J Nucl Med. 1995 Dec;39(4 Suppl 1):111-2.

Abstract

We evaluated the sensitivity of 111In-Octreotide scintigraphy in the diagnosis of pancreatic insulinoma in a selected number of patients. In addition, we compared the results of scintigraphy with those of other conventional diagnostic techniques. Seven patients with surgically confirmed insulinoma (< 1.5 cm in diameter) of the pancreas were studied. Before surgery, patients underwent arteriography with Ca-gluconate, CT scan, and 111In-Octreotide scintigraphy. 111In-Octreotide scintigraphy showed a higher diagnostic specificity (85%) than selective arteriography (83%) or CT scan (57%). We conclude that 111In-Octreotide scintigraphy should always be performed before surgery in cases of pancreatic insulinoma and that a SPECT acquisition should be performed both 6 and 24 hours post-injection in order to increase the diagnostic sensitivity of the test.

Publication types

  • Comparative Study

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Angiography
  • Calcium Gluconate
  • Diagnostic Imaging
  • Female
  • Humans
  • Indium Radioisotopes*
  • Insulinoma / diagnostic imaging*
  • Insulinoma / surgery
  • Male
  • Middle Aged
  • Octreotide / analogs & derivatives*
  • Pancreatic Neoplasms / diagnostic imaging*
  • Pancreatic Neoplasms / surgery
  • Radiopharmaceuticals*
  • Sensitivity and Specificity
  • Tomography, Emission-Computed, Single-Photon*
  • Tomography, X-Ray Computed

Substances

  • Indium Radioisotopes
  • Radiopharmaceuticals
  • indium-111-octreotide
  • Octreotide
  • Calcium Gluconate